Table 1 Design and outcomes of the studies included in the meta-analysis
Num | Research | Total patients | Median follow-up | SGLT2 inhibitor | EF at baseline | DM status At baseline | Primary outcomes |
|---|---|---|---|---|---|---|---|
1 | EMPEROR-Preserved | 5988 | 26.2 months | Empagliflozin | EF > 40% | DM/non-DM | Cardiovascular death or hospitalization for heart failure |
2 | SOLOIST-WHF | 256 | 9.2 months | Sotagliflozin | EF ≥ 50% | DM | Death from cardiovascular causes or hospitalization for HF |
3 | DELIVER | 6263 | 28.1 months | Dapagliflozin | EF > 40% | DM/non-DM | An unplanned hospitalization for HF or an urgent visit for HF, or cardiovascular death |
4 | DECLARE-TIMI 58 | 808 | 50.4 months | Dapagliflozin | EF > 45% | DM | Cardiovascular death or HF hospitalization |
5 | VERTIS-CV | 1007 | 36.0 months | Ertugliflozin | EF > 45% | DM | The time to first major adverse cardiovascular event |
6 | SCORED | 1667 | 16 months | Sotagliflozin | EF ≥ 50% | DM | The first occurrence of a major adverse cardiovascular event |